(PDN) is the most common complication of both type 1 and 2 diabetes and occurs in more than half of affected individuals in both hospital and clinic settings.
According to DelveInsight s estimates, the total prevalent cases of selected indications for Chronic Pain associated with Painful Diabetic Neuropathy were
7,670,318 cases in the 7MM in
2018 and are expected to get increased by
2030. The 3,782,136 cases in the same year.
Looking forward to the
Medical device technology market for PDN, two technologies are available in the Chronic Pain associated with Painful Diabetic Neuropathy market approved over the years by the
FDA and
EMA.
Transcutaneous electrical stimulation (TENS) is one low-cost option that patients can administer at home and used as a Diabetic Peripheral Neuropathy treatment.
Chronic Pain associated with Painful Diabetic Neuropathy Market Expected to Rise by a CAGR of 15 18% by 2026, Estimates DelveInsight
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Chronic Pain associated with Painful Diabetic Neuropathy Market Expected to Rise by a CAGR of 15 18% by 2026, Estimates DelveInsight
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.